Papers 4329
1 page of 433 pages (4,329 results)
#1Megumi Murata (Primate Research Institute)
#2Jun-ichirou Yasunaga (Kyoto University)H-Index: 29
Last. Takuo Mizukami (NIH: National Institutes of Health)H-Index: 13
view all 12 authors...
Simian T-cell leukemia virus type 1 (STLV-1) is disseminated among various non-human primate species and is closely related to human T-cell leukemia virus type 1 (HTLV-1), the causative agent of adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. Notably, the prevalence of STLV-1 infection in Japanese macaques (JMs) is estimated to be > 60%, much greater than that in other non-human primates; however, the mechanism and mode of STLV-1 transmission remain unknown. ...
#1Brandon Spencer Jackson (University of Pretoria)H-Index: 2
#2Julien Nunes Goncalves (University of Pretoria)
Last. Etheresia Pretorius (Stellenbosch University)H-Index: 35
view all 3 authors...
BACKGROUND Patients infected with the human immunodeficiency virus (HIV) are more prone to systemic inflammation and pathological clotting, and many may develop deep vein thrombosis (DVT) as a result of this dysregulated inflammatory profile. Coagulation tests are not routinely performed unless there is a specific reason. METHODS We recruited ten healthy control subjects, 35 HIV negative patients with deep vein thrombosis (HIV negative-DVT), and 13 HIV patients with DVT (HIV positive-DVT) on the...
BACKGROUND: The continued persistence of HIV-1 as a public health concern due to the lack of a cure calls for the development of new tools for studying replication of the virus. Here, we used NanoLuc, a small and extremely bright luciferase protein, to develop an HIV-1 bioluminescent reporter virus that simplifies functional measurement of virus particle production. RESULTS: The reporter virus encodes a Gag protein containing NanoLuc inserted between the matrix (MA) and capsid (CA) domains of Ga...
#1Tomas Bastys (MPG: Max Planck Society)H-Index: 2
#2Vytautas Gapsys (MPG: Max Planck Society)H-Index: 11
Last. Olga V. Kalinina (MPG: Max Planck Society)H-Index: 13
view all 8 authors...
BACKGROUND: HIV-1 can develop resistance to antiretroviral drugs, mainly through mutations within the target regions of the drugs. In HIV-1 protease, a majority of resistance-associated mutations that develop in response to therapy with protease inhibitors are found in the protease's active site that serves also as a binding pocket for the protease inhibitors, thus directly impacting the protease-inhibitor interactions. Some resistance-associated mutations, however, are found in more distant reg...
#1Maria Omsland (NIH: National Institutes of Health)H-Index: 5
#2Micol Silic-BenussiH-Index: 14
Last. Genoveffa Franchini (NIH: National Institutes of Health)H-Index: 71
view all 10 authors...
: Human T cell leukemia virus type-1 (HTLV-1) was the first retrovirus found to cause cancer in humans, but the mechanisms that drive the development of leukemia and other diseases associated with HTLV-1 infection remain to be fully understood. This review describes the functional properties of p13, an 87-amino acid protein coded by HTLV-1 open reading frame II (orf-II). p13 is mainly localized in the inner membrane of the mitochondria, where it induces potassium (K+) influx and reactive oxygen ...
#1Bei Xue (STU: Shantou University)
#2Tiansheng Zeng (STU: Shantou University)H-Index: 5
Last. David J. KelvinH-Index: 52
view all 7 authors...
BACKGROUND: Human endogenous retroviruses (HERVs), suspected to be transposition-defective, may reshape the transcriptional network of the human genome by regulatory elements distributed in their long terminal repeats (LTRs). HERV-K (HML-2), the most preserved group with the least number of accumulated of mutations, has been associated with aberrant gene expression in tumorigenesis and autoimmune diseases. Because of the high sequence similarity between different HERV-Ks, current methods have li...
#1Nathalie Chazal (CNRS: Centre national de la recherche scientifique)H-Index: 15
#2Hugues de Rocquigny (French Institute of Health and Medical Research)H-Index: 22
Last. Jean-Luc Darlix (UDS: University of Strasbourg)H-Index: 51
view all 7 authors...
#1Yash Agarwal (University of Pittsburgh)
#2Cole Beatty (University of Pittsburgh)
Last. Moses T. Bility (University of Pittsburgh)H-Index: 13
view all 7 authors...
The development of safe and effective combination antiretroviral therapies for human immunodeficiency virus (HIV) infection over the past several decades has significantly reduced HIV-associated morbidity and mortality. Additionally, antiretroviral drugs have provided an effective means of protection against HIV transmission. Despite these advances, significant limitations exist; namely, the inability to eliminate HIV reservoirs, the inability to reverse lymphoid tissues damage, and the lack of ...
#1Matthew D. Marsden (UCI: University of California, Irvine)H-Index: 1
Significant advances in the treatment of HIV infection have been made in the last three decades. Antiretroviral therapy (ART) is now potent enough to prevent virus replication and stop disease progression. However, ART alone does not cure the infection, primarily because HIV can persist in stable long-term reservoir cells including latently-infected CD4 + T cells. A central goal of the HIV research field is to devise strategies to eliminate these reservoirs and thereby develop a cure for HIV. Th...
1 CitationsSource
Top fields of study